Neurocrine Biosciences Completes Soleno Therapeutics Acquisition
NBIX sits 35% above its 52-week low of $117.4.
Summary
Neurocrine Biosciences has announced the completion of its acquisition of Soleno Therapeutics. This strategic move expands NBIX's product pipeline and strengthens its position in the biopharmaceutical market. The completion of this deal removes any lingering uncertainty regarding the transaction and integrates Soleno's assets and capabilities into Neurocrine's operations. Traders will now focus on the financial implications of the integration and any updated guidance from Neurocrine regarding the combined entity's future performance.
At the time of this announcement, NBIX was trading at $158.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $117.40 to $162.39. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.